Stage Alpha
Stage Alpha redefines when cancer begins, and when prevention can make its greatest impact.
Redefining the Starting Line
Conventional oncology staging begins at Stage 0, when pathology is already localized, and a lesion is visible. But cancer does not begin there. Converging evidence from circulating tumor DNA, radiomics, immune profiling, and multi-omic biomarkers demonstrates that malignant biology is active well before any lesion can be seen.
Stage Alpha describes that window: a biologically active, preclinical state in which cancer is detectable, but no tumor has yet localized. It is the earliest point at which interception is possible, and where prevention, immune optimization, and individualized surveillance have the greatest potential to alter the outcome.
The Stage Alpha Framework
PreOncology is the medical discipline dedicated to detecting, interpreting, and intervening at the earliest stage at which cancer can be definitively identified. It does not require that cancer be invisible or pre-symptomatic. It requires only that it be caught at the earliest point the Stage Alpha Operating System™ (patent pending) can make a confident, actionable determination.
Conventional oncology asks what stage a cancer has reached. PreOncology asks something different: given what we know about this individual’s biology, what is the earliest point at which we can act with confidence? That shift in question is what separates surveillance from prevention.
Genomic Signals
An individual’s DNA, read once and continuously reinterpreted as science advances. Identifies inherited variants and mutations that increase cancer risk before any symptom appears.
Clinical signals Monitored
Circulating Biomarkers
Fragments of tumor-related material that cancer cells shed into the bloodstream and are detectable long before a mass forms. Includes DNA, proteins, and metabolic signals.
Clinical signals Monitored
Imaging Signals
Advanced imaging analyzed by AI to detect tissue-level changes that fall below the threshold of conventional radiology, patterns that precede a visible tumor.
Clinical signals Monitored
Radiomic anomaly scores
AI-detected tissue changesWhole-body MRIPre-mass formation findings
Biochemical Signals
Persistent shifts in blood-based markers that, in combination with other signals, indicate abnormal biological activity at the cellular level.
Clinical signals Monitored
Tumor-associated biomarkers
Inflammation and immune markersMetabolic and hormone-related markers
Organ function and tissue-stress markers
Persistent abnormal patterns
The Infrastructure to Act on What the Science Is Finding
Until now, the preclinical window has been the one interval in oncology with no structured clinical framework behind it. The PreOncology Program™ changes that, giving physicians the infrastructure and specialist support to act on what the science is finding, and giving members the confidence that the signals conventional screening was never designed to find are being monitored on their behalf.
